2024-10-25 15:43:27,616 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:27,618 - INFO - Run 0:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing CDC documents] Well, Philip, looks like our models were spot on again regarding the mpox risk assessment.

Philip Tetlock: Indeed. Our models gave it a 12.3% probability that the CDC would raise their risk assessment above "Low" before October 1st. The July assessment of "Very Low" remained unchanged through September.

Nate: The data supported our prediction. Despite concerns about clade I mpox in Sub-Saharan Africa, U.S. vaccination rates and existing immunity from the 2022 outbreak provided significant protection.

Philip: Right. The combination of limited domestic transmission, available treatments, and high population immunity in at-risk groups kept the risk assessment stable. Even with CDC's promised update, our models showed minimal likelihood of escalation.

Nate: Another win for superforecasting. Sometimes the most accurate prediction is that things will stay the same.

2024-10-25 15:43:33,694 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:33,694 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:33,695 - INFO - Run 1:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [examining data on his screen] Well, Philip, our models were spot on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models gave only a 12.5% probability of the risk level exceeding "Low" by October.

Nate: The key factors were strong vaccination rates in vulnerable populations and the contained outbreak in Sub-Saharan Africa. Even with CDC's mention of updating their assessment, our models showed minimal risk of escalation.

Philip: Correct. The historical data from 2022-2023 outbreaks demonstrated that summer seasonality wouldn't significantly impact transmission this time. The robust public health infrastructure and improved treatment access kept the risk assessment stable.

Nate: Another win for superforecasting. Our models predicted no, with 87.5% confidence, and that's exactly what happened.

2024-10-25 15:43:33,695 - INFO - Run 1:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [examining data on his screen] Well, Philip, our models were spot on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models gave only a 12.5% probability of the risk level exceeding "Low" by October.

Nate: The key factors were strong vaccination rates in vulnerable populations and the contained outbreak in Sub-Saharan Africa. Even with CDC's mention of updating their assessment, our models showed minimal risk of escalation.

Philip: Correct. The historical data from 2022-2023 outbreaks demonstrated that summer seasonality wouldn't significantly impact transmission this time. The robust public health infrastructure and improved treatment access kept the risk assessment stable.

Nate: Another win for superforecasting. Our models predicted no, with 87.5% confidence, and that's exactly what happened.

2024-10-25 15:43:39,860 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:39,860 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:39,860 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:39,860 - INFO - Run 2:
[Scene: A dimly lit coffee shop in Washington D.C., October 2nd, 2024. Nate Silver and Philip Tetlock are discussing over steaming cups of coffee.]

Nate: So Phil, about that mpox risk assessment prediction - our models nailed it again.

Philip: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models gave only a 12.5% probability of the risk level exceeding "Low" by October 1st.

Nate: The Sub-Saharan Africa clade I outbreak was concerning, but the robust US healthcare infrastructure and high vaccination rates among at-risk populations kept the domestic risk contained.

Philip: Exactly. While we tracked increasing cases in Africa through August, the US surveillance data showed no significant domestic transmission patterns that would have warranted an elevated risk assessment.

Nate: Another successful forecast. Sometimes the most accurate predictions are the ones that recognize system stability, even amid external pressures.

[They clink their coffee cups]

2024-10-25 15:43:39,860 - INFO - Run 2:
[Scene: A dimly lit coffee shop in Washington D.C., October 2nd, 2024. Nate Silver and Philip Tetlock are discussing over steaming cups of coffee.]

Nate: So Phil, about that mpox risk assessment prediction - our models nailed it again.

Philip: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models gave only a 12.5% probability of the risk level exceeding "Low" by October 1st.

Nate: The Sub-Saharan Africa clade I outbreak was concerning, but the robust US healthcare infrastructure and high vaccination rates among at-risk populations kept the domestic risk contained.

Philip: Exactly. While we tracked increasing cases in Africa through August, the US surveillance data showed no significant domestic transmission patterns that would have warranted an elevated risk assessment.

Nate: Another successful forecast. Sometimes the most accurate predictions are the ones that recognize system stability, even amid external pressures.

[They clink their coffee cups]

2024-10-25 15:43:39,860 - INFO - Run 2:
[Scene: A dimly lit coffee shop in Washington D.C., October 2nd, 2024. Nate Silver and Philip Tetlock are discussing over steaming cups of coffee.]

Nate: So Phil, about that mpox risk assessment prediction - our models nailed it again.

Philip: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models gave only a 12.5% probability of the risk level exceeding "Low" by October 1st.

Nate: The Sub-Saharan Africa clade I outbreak was concerning, but the robust US healthcare infrastructure and high vaccination rates among at-risk populations kept the domestic risk contained.

Philip: Exactly. While we tracked increasing cases in Africa through August, the US surveillance data showed no significant domestic transmission patterns that would have warranted an elevated risk assessment.

Nate: Another successful forecast. Sometimes the most accurate predictions are the ones that recognize system stability, even amid external pressures.

[They clink their coffee cups]

2024-10-25 15:43:46,015 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:46,015 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:46,015 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:46,015 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:46,016 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing data on his monitor] Well, Philip, our models were spot-on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models calculated just a 12.5% probability of the risk level exceeding "Low" by October.

Nate: The key factors were really clear - high population immunity from previous outbreaks and vaccinations, plus effective treatments being widely available. Even with that concerning spread in Sub-Saharan Africa, the US healthcare infrastructure was well-prepared.

Philip: Exactly. While we monitored the situation closely, the data through August showed no significant uptick in US cases. The CDC maintained their "Very Low" assessment through September, just as our probability models predicted.

Nate: Another win for superforecasting. Sometimes the boring prediction is the right one.

2024-10-25 15:43:46,016 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing data on his monitor] Well, Philip, our models were spot-on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models calculated just a 12.5% probability of the risk level exceeding "Low" by October.

Nate: The key factors were really clear - high population immunity from previous outbreaks and vaccinations, plus effective treatments being widely available. Even with that concerning spread in Sub-Saharan Africa, the US healthcare infrastructure was well-prepared.

Philip: Exactly. While we monitored the situation closely, the data through August showed no significant uptick in US cases. The CDC maintained their "Very Low" assessment through September, just as our probability models predicted.

Nate: Another win for superforecasting. Sometimes the boring prediction is the right one.

2024-10-25 15:43:46,016 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing data on his monitor] Well, Philip, our models were spot-on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models calculated just a 12.5% probability of the risk level exceeding "Low" by October.

Nate: The key factors were really clear - high population immunity from previous outbreaks and vaccinations, plus effective treatments being widely available. Even with that concerning spread in Sub-Saharan Africa, the US healthcare infrastructure was well-prepared.

Philip: Exactly. While we monitored the situation closely, the data through August showed no significant uptick in US cases. The CDC maintained their "Very Low" assessment through September, just as our probability models predicted.

Nate: Another win for superforecasting. Sometimes the boring prediction is the right one.

2024-10-25 15:43:46,016 - INFO - Run 3:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024]

Nate Silver: [reviewing data on his monitor] Well, Philip, our models were spot-on again about the mpox risk assessment.

Philip Tetlock: Indeed. Given the CDC's July assessment of "Very Low" risk and the limited spread in the US, our models calculated just a 12.5% probability of the risk level exceeding "Low" by October.

Nate: The key factors were really clear - high population immunity from previous outbreaks and vaccinations, plus effective treatments being widely available. Even with that concerning spread in Sub-Saharan Africa, the US healthcare infrastructure was well-prepared.

Philip: Exactly. While we monitored the situation closely, the data through August showed no significant uptick in US cases. The CDC maintained their "Very Low" assessment through September, just as our probability models predicted.

Nate: Another win for superforecasting. Sometimes the boring prediction is the right one.

2024-10-25 15:43:51,605 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:51,605 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:51,605 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:51,605 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:51,605 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2024-10-25 15:43:51,605 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024. Nate Silver and Philip Tetlock are reviewing forecasts.]

Nate: "So, about the CDC's mpox risk assessment - our models were spot on again."

Tetlock: "No surprise there. Given the July 8th 'Very Low' assessment and the limited spread in the US, our models gave only a 12.5% chance of the risk level exceeding 'Low' by October."

Nate: "Right. The key factors were the effective containment measures and high immunity levels from previous vaccination campaigns. Even with that concerning spread in Sub-Saharan Africa, the US population maintained strong protection."

Tetlock: "The CDC's updated assessment maintained the 'Very Low' risk level, exactly as our models predicted. The combination of robust surveillance systems and quick response capabilities kept the probability of escalation minimal."

Nate: "Another win for superforecasting. Sometimes the simplest answer is the right one."

2024-10-25 15:43:51,605 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024. Nate Silver and Philip Tetlock are reviewing forecasts.]

Nate: "So, about the CDC's mpox risk assessment - our models were spot on again."

Tetlock: "No surprise there. Given the July 8th 'Very Low' assessment and the limited spread in the US, our models gave only a 12.5% chance of the risk level exceeding 'Low' by October."

Nate: "Right. The key factors were the effective containment measures and high immunity levels from previous vaccination campaigns. Even with that concerning spread in Sub-Saharan Africa, the US population maintained strong protection."

Tetlock: "The CDC's updated assessment maintained the 'Very Low' risk level, exactly as our models predicted. The combination of robust surveillance systems and quick response capabilities kept the probability of escalation minimal."

Nate: "Another win for superforecasting. Sometimes the simplest answer is the right one."

2024-10-25 15:43:51,605 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024. Nate Silver and Philip Tetlock are reviewing forecasts.]

Nate: "So, about the CDC's mpox risk assessment - our models were spot on again."

Tetlock: "No surprise there. Given the July 8th 'Very Low' assessment and the limited spread in the US, our models gave only a 12.5% chance of the risk level exceeding 'Low' by October."

Nate: "Right. The key factors were the effective containment measures and high immunity levels from previous vaccination campaigns. Even with that concerning spread in Sub-Saharan Africa, the US population maintained strong protection."

Tetlock: "The CDC's updated assessment maintained the 'Very Low' risk level, exactly as our models predicted. The combination of robust surveillance systems and quick response capabilities kept the probability of escalation minimal."

Nate: "Another win for superforecasting. Sometimes the simplest answer is the right one."

2024-10-25 15:43:51,605 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024. Nate Silver and Philip Tetlock are reviewing forecasts.]

Nate: "So, about the CDC's mpox risk assessment - our models were spot on again."

Tetlock: "No surprise there. Given the July 8th 'Very Low' assessment and the limited spread in the US, our models gave only a 12.5% chance of the risk level exceeding 'Low' by October."

Nate: "Right. The key factors were the effective containment measures and high immunity levels from previous vaccination campaigns. Even with that concerning spread in Sub-Saharan Africa, the US population maintained strong protection."

Tetlock: "The CDC's updated assessment maintained the 'Very Low' risk level, exactly as our models predicted. The combination of robust surveillance systems and quick response capabilities kept the probability of escalation minimal."

Nate: "Another win for superforecasting. Sometimes the simplest answer is the right one."

2024-10-25 15:43:51,605 - INFO - Run 4:
[Scene: A dimly lit office at FiveThirtyEight headquarters, October 2, 2024. Nate Silver and Philip Tetlock are reviewing forecasts.]

Nate: "So, about the CDC's mpox risk assessment - our models were spot on again."

Tetlock: "No surprise there. Given the July 8th 'Very Low' assessment and the limited spread in the US, our models gave only a 12.5% chance of the risk level exceeding 'Low' by October."

Nate: "Right. The key factors were the effective containment measures and high immunity levels from previous vaccination campaigns. Even with that concerning spread in Sub-Saharan Africa, the US population maintained strong protection."

Tetlock: "The CDC's updated assessment maintained the 'Very Low' risk level, exactly as our models predicted. The combination of robust surveillance systems and quick response capabilities kept the probability of escalation minimal."

Nate: "Another win for superforecasting. Sometimes the simplest answer is the right one."

